Diagnostic kit for Predicting Osteoarthritis Severity and Drug Efficacy

Dvir-Ginzberg Mona, HUJI, Faculty of Dental Medicine, Institute of Dental Sciences


Life Sciences and Biotechnology   


Osteoarthritis, Diagnostics



Osteoarthritis is a degenerative joint disease that occurs most frequently in the hands, hips, and knees and affects over 32.5 million US adults.

With OA, the cartilage within a joint begins to break down and the underlying bone begins to change. These changes usually develop slowly and get worse over time. OA can cause pain, stiffness, and swelling. In some cases, it also causes reduced function and disability; some people are no longer able to do daily tasks or work.


Our innovation:

We showed that cleavage of the protein SIRT1, which occurs during joint inflammation, alters the cartilage of the cell. Furthermore, Senolytic drugs administration is reflective in the serum of SIRT1 variants levels and correlates with structural preservation of the joint.

Based on these findings, our technology relates to:

  • The use of variants of the protein SIRT1 as biomarkers to early stages of Osteoarthritis
  • Using Senolytic drugs to reduce the levels of SIRT1 variants in blood leading to mitigation of Osteoarthritis severity
  • A drug-efficacy test for clinical and preclinical stages of development, assessing Senolytic drug efficacy for the treatment of Osteoarthritis


Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
Contact ME: